Page 1

EX - 99.1 2 d209776dex991.htm EX - 99.1 atai LIFE SCIENCES Exhibit 99.1 atai Life Sciences Reports Second Quarter 2021 Financial Results and Business Update -Successfully completed Initial Public Offering on Nasdaq raising $ 258.8 million in gross proceeds , including the underwriters ' over - allotment -Received $ 20 million upfront payment from Otsuka as part of the first major collaboration between a biopharmaceutical company developing psychedelics and large pharma -Advancement of 11 therapeutic programs , including initiation of Recognify's Phase 2 and GABA's Phase 1 trials -18 significant catalysts across atai's platform anticipated over next 18 months including two clinical trials to be completed and four clinical trials to be initiated in 2021 -Solidified leadership position with strong cash position of $ 453.6 million to advance our current programs and incubate , acquire and invest in new programs -Company to host a webcast and conference call today at 08:30 am EDT BERLIN and NEW YORK , August 16 , 2021 ( GLOBE NEWSWIRE ) atai Life Sciences N.V. ( Nasdaq : ATAI ) ( “ atai " ) , a clinical - stage biopharmaceutical company aiming to transform the treatment of mental health disorders , today reported its financial results for the second quarter ended June 30 , 2021 and provided a corporate update . " In the second quarter of 2021 , we made significant advancements to build our business and successfully completed an initial public offering on Nasdaq , raising approximately US $ 258.8 million in gross proceeds , " said Florian Brand , CEO and co - founder of atai . " We have the financial resources to maximize the value of our decentralized drug development platform for improved probability of clinical success and leverage the value of our transformative pipeline . 2021 continues to be a pivotal year for atai with multiple upcoming catalysts across our expanding pipeline . " Q2 Corporate Updates Received $ 20 million as part of Perception's collaboration with Otsuka for the development of R - ketamine , the first major collaboration between a biopharmaceutical company developing psychedelics and large pharma . Entered a strategic partnership with IntelGenx , a leader in pharmaceutical films . As part of the strategic partnership , IntelGenx will exclusively partner with atai to develop compounds for the prevention or treatment of mental health diseases or disorders . Announced InnarisBio in partnership with UniQuest , Australia's leading university technology transfer company commercializing the research of The University of Queensland ( UQ ) , to develop a novel sol - gel - based intranasal drug delivery technology to improve treatments for mental health disorders .